SCHEMBL6742776

SCHEMBL6742776

N#CN(C(N)=O)C(=O)[CH]CS(=O)(=O)Cc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 1/20 0.38
PRSS1 P07477 3/20 0.37
PRSS2 P07478 3/20 0.37
PRSS3 P35030 3/20 0.37
F2 P00734 2/20 0.37
HSD17B10 Q99714 2/20 0.36
FPR1 P21462 1/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA5A P35218 1/20 0.36
CA9 Q16790 1/20 0.36
HSP90AA1 P07900 1/20 0.34
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
MMP13 P45452 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
TSHR P16473 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6021436 0.80 ALDH1A1 (0.37) ALDH1A1KDM4ECA1CA2SNCA
SCHEMBL6264968 0.78 GPR52 (0.39) ALDH1A1SMN1; SMN2SNCA
SCHEMBL6062788 0.74 SMN1; SMN2 (0.40) ALDH1A1KDM4ECA1CA2CA9
SCHEMBL6019621 0.68 CA2 (0.40) ALDH1A1KDM4ECA2
SCHEMBL17048988 0.66 CA2 (0.41) ALDH1A1PRSS1PRSS2PRSS3F2
SCHEMBL17046824 0.66 CA2 (0.41) ALDH1A1PRSS1PRSS2PRSS3F2
SCHEMBL17046823 0.66 CA2 (0.41) ALDH1A1PRSS1PRSS2PRSS3F2
SCHEMBL6252815 0.66 BACE1 (0.35) ALDH1A1KDM4ECA5ASMN1; SMN2NPC1
SCHEMBL3929825 0.65 ALDH1A1 (0.58) ALDH1A1KDM4EPRSS1PRSS2PRSS3
SCHEMBL5153729 0.64 HSP90AA1 (0.51) ALDH1A1KDM4EPRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors AXYS PHARMACEUTICALS, INC. 2004-01-22 US disclosed
US-6492362-B1 Compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS, INC. 2002-12-10 US disclosed
EP-1212302-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-06-12 EP disclosed
WO-2001019796-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors CTSS, CTSB, CTSE ALDH1A1 4044/4885KDM4E 4465/4885PRSS1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.